# Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

> **NCT00119262** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 226 (actual)

## Conditions studied

- Male Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** bevacizumab
- **DRUG:** paclitaxel
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **RADIATION:** radiation therapy
- **DRUG:** tamoxifen citrate
- **DRUG:** aromatase inhibition therapy

## Key facts

- **NCT ID:** NCT00119262
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-09
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119262, "Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00119262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*